Ziemek Dental Laboratory, Inc.
$61.9K 4 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Orphalan Inc
Orphalan Inc reported $61,880.39 across General Payments, Research, and Ownership to 706 physicians and teaching hospitals across 706 transactions.
- $61.9K Below-median payer
- All-tracks total
- 706 Above-median volume
- Transactions
- 706 Above-median reach
- Recipients
- −$9.0K
- General Payments vs PY2023
Orphalan Inc reported $61,880.39 across all CMS Open Payments tracks (General + Research + Ownership) to 706 physicians and teaching hospitals in Program Year 2024 - ranking #1299 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $61,880.39, averaging $87.65 per recipient.
How Orphalan Inc's $61.9K all-tracks total breaks down
Orphalan Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
16/100
Total payments
F
11/100
Transaction volume
F
15/100
Physician reach
F
15/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer orphalan-inc Orphalan Inc
$61.9K · #1299/1,925 · 0.0% industry · PY2024
- TOT $61.9K
- RANK #1299
- SHARE 0.0%
- TXN 706
- RCP 706
- CAT 2
- GEN $61.9K
- ΔGEN −$9.0K
- TOP1 5.8%
- PY 2024
Volume peers
Nearest volume peer: Ziemek Dental Laboratory, Inc. ($61.9K)
Orphalan Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Orphalan Inc's CMS-reported General Payments decreased by $9.0K (−12.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: ORPHALAN INCPY2024: ORPHALAN INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $70,847.32
- PY2024
- $61,880.39
What the Data Shows for Orphalan Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Orphalan Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
14 transactions worth $42.0K make "Honoraria" the top general-payment category in the 2-category breakdown below, 67.9% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Honoraria" leads Orphalan Inc's 2-category general-payment breakdown at $42.0K, 67.9% of the reported total.
How Orphalan Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $42.0K | 14 | 67.9% |
| Food and Beverage | $19.9K | 692 | 32.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $16,013.31 (25.9%) of $61,880.39 in this company's General Payments records across 499 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Orphalan Inc
The five named recipients with the highest reported General Payments from this company
- 1
Amanda Ching-Wun Cheung
$3,600.00 across 1 reported transactions
- 2
Parvez Mantry
$3,149.07 across 2 reported transactions
- 3
Satheesh Padmanabhan Nair
$3,133.57 across 2 reported transactions
- 4
Kris Kowdley
$3,101.42 across 5 reported transactions
- 5
Sammy Saab
$3,029.25 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Orphalan Inc's spend rank (#1299 of 1,925, bottom 33% by spend) and concentration rank (#1,427 of 1,838, bottom 22% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Teleflex LLC : $5.6M total payments, HHI 349
- Carl Zeiss Meditec USA, Inc. : $719.3K total payments, HHI 348
- Checkpoint Surgical, Inc : $293.7K total payments, HHI 348
- Medline Industries LP : $1.9M total payments, HHI 347
- Olympus Corporation : $904.0K total payments, HHI 343
- Coherus Biosciences Inc. : $361.8K total payments, HHI 343
- Orphalan Inc (this company) : $61.9K total payments, HHI 342
- Dutch Ophthalmic, USA : $85.0K total payments, HHI 342
- BonaliveInc : $3.3K total payments, HHI 342
- Davol Inc. : $4.4M total payments, HHI 337
- Eli Lilly Export S.A. Puerto Rico Branch : $47.2K total payments, HHI 334
- Profound Medical Corp. : $125.2K total payments, HHI 329
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Orphalan Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Orphalan Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Orphalan Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ziemer USA
$62.1K 17 recipients
Compare payment profiles
Remington Medical, Inc.
$61.7K 23 recipients
Compare payment profiles
PolyMedics Innovations Inc.
$62.1K 242 recipients
Compare payment profiles
Kowa Research Institute, Inc.
$61.6K 101 recipients
Compare payment profiles
SpineGuard, Inc.
$62.4K 27 recipients
Compare payment profiles
Put this to use
Orphalan Inc ranks #1299 of 1,925 by all-tracks total payments, led by "Honoraria".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Orphalan Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.